Overcoming Real World Challenges in the
of Metastatic Bladder Cancer: How Advances in
Immunotherapy are Improving Patient Outcomes
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in the live
session, you are not eligible for continuing education credits from
This activity is valid from March 10, 2018 to March 31, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from
Merck & Co
Bladder cancer, also known as urothelial carcinoma, is the ninth
leading cause of cancer death in the United States. Long-term
survival for patients diagnosed with metastatic bladder cancer is
poor, with only 5% of patients surviving for 5 years or more. Due to
the role of the immune system in oncogenesis, therapy has become
clearer across cancer types, and new approaches are emerging with
important benefits in metastatic bladder cancer. In particular,
immune checkpoint inhibitors such as programmed death-1 (PD-1), PD-ligand
1 (PD-L1), and cytotoxic T lymphocyte–associated protein 4 (CTLA-4)
inhibitors are changing the treatment paradigm. Checkpoint
inhibitors have shown efficacy in patients with metastatic bladder
cancer in both the second-line setting and the first-line settings.
These inhibitors target proteins that are expressed at high levels
on some cancer cells, while others target immune cells. All of these
new options allow the immune system to be more active against tumor
cells. As immune checkpoint blockade inhibitors in the treatment of
advanced bladder cancer have demonstrated significant enhancements
to clinical outcomes.
Upon Completion of this
activity, participants will be able to:
Analyze immunotherapy options in the
first-line treatment of metastatic bladder cancer
Assess the safety & efficacy data of
Anti–PD-1 immunotherapy in metastatic bladder cancer
Explore best practices for the
incorporation of immune checkpoint inhibitors into existing
Discuss strategies for the
prevention, detection, and optimal management of immune-related
||Matthew Campbell, MD, MS
Department of Genitourinary Medical Oncology
The University of Texas MD Anderson Cancer Center
Campbell serves on an advisory board for AstraZeneca,
Eisai and EMD Serono. His presentation has been peer
reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for
NAMCP designates this enduring material for a maximum of 1 AMA PRA
Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by an educational grant from
Merck & Co
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue